- Hoth Therapeutics has **expanded its intellectual property portfolio** for its lead topical therapeutic candidate, HT-001, by filing multiple U.S. Provisional Patent Applications.  **[1711786_20250924NY81916:0]** 
- The new patent filings cover novel dermatological indications, including **Drug-Induced Hypersensitivity Syndrome, Radiotherapy-Induced Rash, and dermatological conditions associated with MENIN Inhibitor Therapy**.  **[1711786_20250924NY81916:0]** 
- This expansion aims to **broaden the commercial and clinical potential of HT-001**, positioning the company to address significant unmet needs in oncology supportive care.  **[1711786_20250924NY81916:0]** 
- HT-001 is designed to improve the tolerability of cancer therapies by mitigating dermatological side effects, potentially enabling patients to **remain on therapy longer**.  **[1711786_20250924NY81916:0]**

Hoth Therapeutics Expands HT-001 Patent Portfolio for New Dermatological Indications

- **Hoth Therapeutics** is advancing its clinical programs, with **HT-001** expanding globally through a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) for its Phase II trial, and **HT-KIT** successfully completing its Good Laboratory Practice (GLP) bioanalytical phase.  **[1711786_20250916NY74072:0]** 
- The company is also progressing its **VA obesity program** in partnership with the U.S. Department of Veterans Affairs.  **[1711786_20250916NY74072:0]** 
- Hoth's Board of Directors approved an expansion of its treasury reserve strategy to include **Ethereum** and **Solana**, alongside **Bitcoin**, allowing for potential purchases of up to **$1 million** in these digital assets.  **[1711786_20250916NY74072:0]** 
- The company has integrated **AI** by adopting Lantern Pharma's PredictBBB.ai platform to enhance data-driven decision-making across its programs.  **[1711786_20250916NY74072:0]**

Hoth Therapeutics Issues Shareholder Update on Clinical Programs and Treasury Strategy

- Hoth Therapeutics' precision antisense candidate, **HT-KIT**, has shown positive findings from multiple preclinical programs, demonstrating compelling anti-tumor efficacy and a clean safety profile.  **[1711786_20250902NY62028:0]** 
- Preclinical models of gastrointestinal stromal tumors (GIST) and systemic mastocytosis showed **significant tumor cell death** within **24 hours** of HT-KIT treatment, with statistically significant tumor shrinkage observed by day 8.  **[1711786_20250902NY62028:0]** 
- In vitro, HT-KIT achieved **over 80% knockdown of KIT expression**, and multi-dose in vivo studies confirmed **no off-target toxicity** across critical organs.  **[1711786_20250902NY62028:0]** 
- GLP-validated bioanalytical results for HT-KIT, conducted by Altasciences Company, Inc., met or **exceeded strict bioanalytical benchmarks**, including 90.5% of Incurred Sample Reanalysis (ISR) values falling within ±30%, which is above the 66.7% regulatory minimum.  **[1711786_20250902NY62028:0]** 
- Hoth Therapeutics plans to integrate this bioanalytical data into its formal GLP toxicology package and is **preparing for an IND submission** and first-in-human trials for HT-KIT.  **[1711786_20250902NY62028:0]**

Hoth Therapeutics (HOTH)